Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00166387
Status:
COMPLETED
Last Update Posted:
2014-03-26
First Post:
2005-09-09
Brief Title:
Hemophilia Inhibitor Genetics Study HIGS
Sponsor:
Skane University Hospital
Organization:
Skane University Hospital
Study Overview
Official Title:
Hemophilia Inhibitor Genetics Study HIGS
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Several non-genetic and genetic factors that could influence the risk of inhibitor development in hemophilia A have been discussed but not fully explored The aim of the HIGS is to identify these genetic factors
Detailed Description:
The objective of the HIGS is to determine host genetic factors other than mutations within the factor VIII gene that are associated with the development of inhibitors in severe hemophilia A and response to antigenic challenge by factor VIII The study will involve three phases enrolling family groups composed of brother pairs and their parents Phase I and siblings a family group composed of a person with severe hemophilia and his parents Phase II and a group of unrelated people with severe hemophilia for the purpose of confirming associations identified in Phases I and II
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None